Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 1463 entries
View as:

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Phase: N/A Priority: Normal
NCT ID: NCT06241599 Org: User:
Start: 02/01/24 End: 02/01/29 Due: 02/01/30

Protein and microRNA Markers for Early Detection of Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03388242 Org: User:
Start: 12/07/17 End: 03/30/20 Due: 03/30/21

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

Phase: N/A Priority: Normal
NCT ID: NCT00816868 Org: User:
Start: 01/31/09 End: 03/31/11 Due: 03/31/12

Intelligent Evaluation and Supervision of Cataract Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05260775 Org: User:
Start: 01/01/19 End: 12/30/21 Due: 12/30/22

Individual vs Cohort Long Distance Advising for Mental Care for Congenital Cataract Guardians

Phase: N/A Priority: Normal
NCT ID: NCT03216655 Org: User:
Start: 07/11/17 End: 08/20/18 Due: 08/20/19

MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06204484 Org: User:
Start: 07/26/23 End: 07/31/28 Due: 07/31/29

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Phase: N/A Priority: Normal
NCT ID: NCT04989621 Org: User:
Start: 08/01/21 End: 08/31/23 Due: 08/31/24

Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01271192 Org: User:
Start: 12/31/10 End: 12/31/20 Due: 12/31/21

Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT05008471 Org: User:
Start: 04/26/21 End: 04/26/22 Due: 04/26/23

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT06749899 Org: User:
Start: 05/04/25 End: 12/01/30 Due: 12/01/31

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03494634 Org: User:
Start: 04/15/18 End: 09/30/20 Due: 09/30/21

FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)

Phase: N/A Priority: Normal
NCT ID: NCT02572141 Org: User:
Start: 01/01/15 End: 04/01/26 Due: 04/01/27

A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05622474 Org: User:
Start: 11/30/22 End: 12/31/28 Due: 12/31/29

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT06675214 Org: User:
Start: 07/30/24 End: 07/31/30 Due: 07/31/31

Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Phase: N/A Priority: Normal
NCT ID: NCT03469479 Org: User:
Start: 03/02/18 End: 03/02/23 Due: 03/02/24

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT04588987 Org: User:
Start: 10/31/20 End: 05/31/24 Due: 05/31/25

Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01216527 Org: User:
Start: 06/30/07 End: 12/31/19 Due: 12/31/20

A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03071289 Org: User:
Start: 06/01/17 End: 03/31/25 Due: 03/31/26

Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT03214731 Org: User:
Start: 01/16/19 End: 09/30/22 Due: 09/30/23

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

Phase: N/A Priority: Normal
NCT ID: NCT03172156 Org: User:
Start: 07/01/17 End: 02/01/20 Due: 02/01/21

Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05020067 Org: User:
Start: 01/12/18 End: 08/17/21 Due: 08/17/22

Uptake of Telemedicine System Trial in Rual Canton

Phase: N/A Priority: Normal
NCT ID: NCT01832077 Org: User:
Start: 01/31/15 End: 04/30/17 Due: 04/30/18

Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05114720 Org: User:
Start: 11/11/21 End: 12/31/28 Due: 12/31/29

Minocycline Treatment for Cystoid Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT05474950 Org: User:
Start: 01/01/19 End: 06/01/25 Due: 06/01/26

Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers

Phase: N/A Priority: Normal
NCT ID: NCT02777801 Org: User:
Start: 06/30/15 End: 06/30/18 Due: 06/30/19